The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.
 
Darren Cowzer
No Relationships to Disclose
 
Abraham Jing-Ching Wu
Stock and Other Ownership Interests - Simphotek
Consulting or Advisory Role - AstraZeneca; MORE Health; NanoVi
Research Funding - CivaTech Oncology
Travel, Accommodations, Expenses - CivaTech Oncology
 
Smita Sihag
No Relationships to Disclose
 
Henry S. Walch
No Relationships to Disclose
 
Bernard J. Park
No Relationships to Disclose
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
 
Ping Gu
No Relationships to Disclose
 
Steven Brad Maron
Stock and Other Ownership Interests - Calithera Biosciences
Consulting or Advisory Role - Basilea; Bicara Therapeutics; Daichi Sankyo; Natera; Novartis
Research Funding - Guardant Health (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bayer
 
Ryan Sugarman
No Relationships to Disclose
 
Sree Bhavani Chalasani
No Relationships to Disclose
 
Marina Shcherba
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Anton Nosov
No Relationships to Disclose
 
Randy Yeh
No Relationships to Disclose
 
Laura H. Tang
No Relationships to Disclose
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IQvia; Lilly/ImClone; Macrogenics; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Imugene; Lilly; Merck; Merck Serono; Michael J. Hennessy Associates; Paradigm; Pfizer; Rgenix; Seagen; Zymeworks
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst)
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Daniela Molena
Honoraria - Bristol-Myers Squibb/Pfizer; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Boston Scientific; Johnson & Johnson; Urogen pharma
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals